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Background During the wave 1 of the influenza A(H1N1)pdm09
virus, Norway appeared to be suffering from high mortality rates.
However, by the end of the pandemic, it was widely reported that
the number of deaths were much lower than previous years.
Objectives The mortality burden from influenza is often assessed
by two different approaches: counting influenza-certified deaths and
estimating the mortality burden using models. The purpose of this
study is to compare the number of reported deaths with results from
two different models for estimating excess mortality during the
pandemic in Norway. Additionally, mortality estimates for the
pandemic season are compared with non-pandemic influenza
seasons.
Methods Numbers on reported influenza A(N1h1)pdm09 deaths
are gived by the Cause of Death Registry at Statistics Norway and an
ad hoc registry at the Norwegian Institute of Public Health. Overall
and Pnemumonia and Influenza certified mortality is modeled using
Poission regression, adjusting for levels of reported influenza-like
illness and seasonal and year-to-year variation.
Results and conclusions Modelling results suggest that the excess
mortality in older age groups is considerably lower during the
pandemic than non-pandemic seasons, but there are indications of
an excess beyond what was reported during the pandemic. This
highlights the benefits of both methods and the importance of
explaining where these numbers come from.
Keywords A(H1N1)pdm09, excess mortality, influenza, modelling,
pandemic, reporting.
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Introduction
The 2009 H1N1 influenza pandemic was the first pandemic
of the twenty-first century, as declared by the World Health
Organization in June 2009. During the first weeks of the
main pandemic wave in Norway in October 2009, it
appeared that Norway was experiencing a higher mortality
rate associated with the influenza A(H1N1)pdm09 virus
than other European countries. However, by the end of the
pandemic period, it was widely reported that there had
been much fewer influenza-related deaths than in previous
years.
It is often hard to discern between influenza and other risk
factors as the cause of death for patients with chronic diseases.
Therefore, one can differentiate between twomain approaches
used to assess the mortality burden.1 One approach is to count
the number of deaths reported to death registries with
influenza as one of the registered direct or underlying causes
of death, with or without laboratory confirmation. The true
mortality burden is assumed to be much higher than what is
reported by these registries1,2 because most often influenza is
not recognized as a contributing factor to death due to varying
clinical presentation of influenza, low awareness among
clinicians and varying practices and availability of testing for
influenza.
The other approach for assessing the mortality burden of
influenza as a contributing factor is by using statistical
models. Typically, these models estimate the excess mortality
as the difference between the observed mortality during an
influenza season and the expected baseline mortality in the
same period if no influenza were present. There are different
ways to determine the baseline mortality, but it is typically
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made using a regression or time series method.2–5 In Norway,
both these approaches have been undertaken for the first year
of the influenza A(H1N1)pdm09 pandemic.
By the use of these two approaches (registries and models),
health authorities’ reporting may lead to confusion. Typi-
cally, one can cite the excess number of deaths from seasonal
influenza when arguing for the importance of public health
measures against influenza, such as vaccination. This strategy
may backfire if the public at another time is presented with
the usually much lower number of registered deaths in the
Cause of Death Registry, without a proper explanation of the
methods.
The objective of this study was to compare the number of
reported influenza-registered deaths with the results from
two different models for estimating the excess mortality due
to influenza during the 2009 pandemic in Norway. This was
to try to understand the real impact of the pandemic on
yearly mortality rates and allow for realistic planning for
future pandemics. Using one of the models, we also wanted
to compare the estimates for the pandemic season with
previous regular influenza seasons.
Methods
Data material
The Norwegian Institute of Public Health (NIPH), in
conjunction with the Directorate of Health, set up an ad
hoc registry of people reported to have died from influenza A
(H1N1)pdm09 during the pandemic. Cases were defined as
any person dying in Norway in the period between April
2009 and April 2010 where laboratory-confirmed influenza A
(H1N1)pdm09 was considered to have significantly contrib-
uted to death. Starting from 20 July 2009, all doctors in
Norway were obliged to immediately notify the Norwegian
Institute of Public Health of any such cases. Following a
notification, we asked the local municipal medical officer to
collaborate with the patient’s family to complete an exhaus-
tive questionnaire and return it to the Directorate of Health
who then removed identifying data before forwarding it to us
at the NIPH.
In addition, we received data from the Cause of Death
Registry at Statistics Norway on the patients where influenza
was coded as a direct or underlying cause of death during the
2009 pandemic. We also received total numbers of Pneu-
monia and Influenza (P&I)-certified deaths per week (using
ICD-10 codes J09-J18) from week 1 in 2000 through week 52
in 2011.
Data on all-cause mortality per week (defined by the ISO
standard), overall and for age groups (0–4, 5–14, 15–64 and
65+), were derived from the National Population Register.
Data were available until week 10 in 2011.
Data on influenza-like illness (ILI) were derived from the
Norwegian Notification System for Infectious Disease
(MSIS). Since autumn 1998, 201 sentinel reporting units
have reported the number of consultations where ILI
diagnosis is given (ICPC-2 code R80) per total number of
consultations per week to the Norwegian Institute of Public
Health (NIPH). As outbreaks of influenza typically take place
during the winter, they are assigned to a pre-defined
influenza season instead of calendar year. Prior to 2009,
numbers were reported from week number 40 each year to
week number 20 the year after, while in 2009 and 2010, ILI
levels were also recorded during the summer (between weeks
20 and 40). To include the 2009 pandemic in the analysis, an
influenza season was defined to extend from week 21 in one
year to week 20 the year after. In seasons where ILI was not
recorded between weeks 21 and 39 (off season), ILI levels
were estimated using linear interpolation. In years with 53
weeks, the last week was disregarded. ILI levels for age groups
(0–4, 5–14, 15–64 and 65+) were included from autumn
2001.
Norwegian population numbers for January 1 each year
were derived from Statistics Norway, together with age-
distributed population numbers for 1 January 2011, used to
estimate age-distributed population numbers for the period
1998–2011.
Estimated excess mortality using a Poisson
regression model
The number of overall deaths per week was modelled using
an overdispersed (quasi) Poisson model similar to the model
in Gran et al.2:
Y ¼ a exp b0 þ b1Weekþ b2 Seasonþ b3 ILIþ b4 ILI Pf g;
(1)
where Y represents the number of overall deaths in a
particular week, the offset term a represents the total
population in Norway by January 1 the corresponding year,
Week is the week number (between 1 and 52), Season is a
factor with a level for every influenza season (1998/1999,
1999/2000, …), ILI is the reported cases of ILI the week
before, P is a factor variable with three levels – one level for
the wave 1 of the 2009 pandemic (weeks 30–40), one level for
the wave 2 (weeks 41–50) and one level for any other week,
and the b’s are the corresponding regression coefficients. The
interaction term ILI 9 P was included to allow for different
impacts of ILI during the two waves of the 2009 H1N1
pandemic than during regular seasonal influenza. The lag of
one week in the ILI variable was chosen as it gave the best fit
with respect to explained variance compared with no lag and
a lag of 2 weeks.
To assess model performance, we also fitted a model
similar to Thomson et al.3 and Foppa et al.,4 using cyclic
terms for seasonal variation, as well as a combination of this
model and the model in Eq. (1), with cyclic terms and a
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seasonal factor. The three models were fitted to predict the
weekly total number of deaths, as well as weekly number of
deaths in age groups. For age-grouped analyses, two different
sets of models were compared: one with weekly total ILI and
one with weekly age group–specific ILI as a predictor. All
three models gave similar estimates of the influenza contri-
bution b3 and of excess mortality (including confidence
intervals). The model in Eq. (1) was therefore chosen as our
final model to stay close to the model in Gran et al.,2 despite
its higher parameterization. The estimated dispersion param-
eter using the model in Eq. (1) on overall data was 175,
against 232 and 243 for the two other models, respectively.
For a more formal model, selection one could use the QAIC
criterion suggested for quasi-models.6
For each week, the estimated excess mortality X^ can be
calculated by:
X^ ¼ Y  Y^ILI¼0; (2)
Where Y is the observed number of deaths that week and
Y^ILI¼0 is the predicted number of deaths when the ILI level is
fixed at 0 when making predictions from the above Poisson
models. Note that when the model is formulated with
seasonal terms as in Eq. (1), using the predicted number of
deaths Y^ instead of Y in the above estimator will give
identical results for overall and per-season estimates of excess
mortality.
Corresponding to Gran et al.,2 due to the nature of our ILI
data, we moderated our estimator in Eq. (2) and calculated:
X^ ¼ Y  Y^ILI¼BL; (3)
where BL is the ever-present baseline of ILI, present also off
season. The constant BL was found as the mean of the lowest
19 weeks (the length of the off-season period) of ILI activity
from every season.
Confidence intervals for the estimates of excess mortality
were found using the 95% bootstrap percentiles from 1000
bootstrap samples, bootstrapping the model residuals.7
The analysis was performed using the GLM package in the
open-source statistical software R, version 2152.8
Estimated excess mortality using the consensus
EuroMOMO protocol
An alternative to the model in Eq. (1) is the model used by
EuroMOMO.9 The aim of the EuroMOMO project was to
develop and strengthen monitoring of mortality across
Europe to enhance management of serious public health
risks such as pandemic influenza, heat waves and cold snaps.
As in the model described above, the main outcome is
excess mortality, defined as observed minus expected mor-
tality for a specified time period. Data analysis involves
modelling of the expected number of deaths for a given
geographical unit and for different population groups. To
compare estimates of excess deaths, a common versatile
statistical model is needed, and the key output of Euro-
MOMO was to provide a European consensus model for
mortality monitoring, which is applicable all over Europe
and which is piloted and ready to implement.
To obtain the baseline mortality (without influenza), a
Poisson regression was modelled on the spring (weeks 16–25)
and autumn (weeks 37–44) periods, to systematically remove
expected winter and summer excess deaths from the
historical data.10 A sine–cosine cycle with a period of
5218 weeks and a trend are included in the model to
control for seasonality and trend representing a modified
Serfling approach.11 The model is fitted using a historical
period of 5 years.
Results
From the designated surveillance at the NIPH of deaths due
to pandemic influenza, a total of 32 fatalities (065 per
100 000 of the population) were registered between April
2009 and April 2010 (Table 1). Two further patients found in
the Cause of Death Registry were not included as their
influenza diagnosis was not laboratory confirmed. Question-
naires were received back for 28.
Only one person was not found to have had a medical
condition that put the person at higher risk from influenza
complications. Ten people were found to have more than one
condition that put them at higher risk. The most common
condition was chronic pulmonary disease. No cases of
vaccine failure were found.
The peak period of deaths from influenza A(H1N1) was
earlier in Norway than that the average of countries in
Europe (Figure 1); however, the mortality rate was consistent
with that seen in other countries.
Table 1. Number of registered influenza deaths in Norway between
April 2009 and April 2010, by gender and age group. Influenza deaths
are deaths were laboratory-confirmed influenza A(H1N1)pdm09 was
considered to have significantly contributed to death
Age Men Women Total
0–9 2 1 3
10–19 1 2 3
20–29 2 1 3
30–39 3 4 7
40–49 2 2 4
50–59 6 1 6
60–69 0 5 5
≥70 0 1 1
Total 16 16 32
Gran et al.
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The numbers of reported deaths by age group for the
pandemic season compared with the season between 1997
and 2008 are presented in Figure 2. The figure indicates a
significantly different age distribution for the deaths in the
pandemic season, with cases spread out in all age groups,
compared with the other seasons where almost all deaths are
found among the elderly population.
With the Poisson regression model in Eq. (1), the
estimated seasonal excess mortality using Eq. (3), from
season 1998/1999 to season 2009/2010, varied from 56 deaths
in the 2009/2010 pandemic season to 1520 deaths in the
1999/2000 season, when analysing all-cause mortality
(Table 2). The mean estimated excess mortality for the
entire period was 766 deaths per season (166 per 100 000
population). Results analysing P&I-certified deaths were
considerably lower, ranging from 394 deaths in the 1999/
2000 season to 72 deaths in the 2007/2008 season, with a
mean estimate of 172 excess deaths per season (37 per
100 000 population). Note, however, that the P&I analysis
does not cover season 1998/1999 and that the first and last
seasons in both analysis do not cover a complete 52 weeks.
In Figure 3, the upper panel shows the observed mortality,
predicted mortality and reported number of ILI cases per
week for the entire period. We see that the predicted
mortality is close to the observed, indicating a good model
fit. The figure also shows how the mortality and ILI peaks
coincided in most seasons, but not in the pandemic 2009/
2010 season. The lower panel of Figure 3 shows the observed
mortality together with the predicted mortality without the
ILI contribution (with 95% confidence intervals for the
latter). The estimated excess mortality is, by the definition in
Eq. (3), found as the difference between these two solid lines.
Analyses were also carried out for age groups. Table 3
shows the effect of ILI on mortality (b3), the effect of the
Figure 1. Mortality rates (per million) from
influenza in the EU/EEA countries (from ECDC)
and in Norway, by week during the first
pandemic year, 2009-2010.
Figure 2. Number of influenza deaths per
million by age group reported to the Cause of
Death Registry for the seasons 1997–2008 on
average (light grey) and to the NIPH for the first
pandemic year, April 2009–April 2010 (dark
grey).
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interaction between ILI and wave 1 and wave 2 of the
pandemic season (b4), the overall mean estimated seasonal
excess mortality and estimated excess mortality in the
pandemic season using the estimator in Eq. (3), for all age
groups and in total. The results are compared with an
analysis using P&I deaths for all age groups. Note that
numbers for all age groups do not equal the sum of the
numbers for age groups alone, as they were estimated using
separate models. We see that the largest effect of ILI on
mortality is in the youngest and oldest age groups. For the
15–64 age group, there is no significant excess mortality. For
the interaction terms, only wave 2 is significant in the 0–4, 5–
14 or 15–64 groups, while in the 65+ group and for overall
data, there is a significant interaction effect both during wave
1 and wave 2. A significant interaction term means that the
ILI effect on mortality is significantly different during the
specific pandemic wave than during the rest of the season. All
the significant effects are negative, meaning that the impact
of ILI during the pandemic was less than in regular seasons.
Further, we see that the results from the pandemic season do
not differ much from the seasonal average for the 0–4, 5–14
and 15–64 age groups, but are much lower than average for
the 65+ group (and then naturally also the overall group).
Note, however, that the uncertainty is very high for estimates
during the pandemic period.
Figure 4 shows the results from the modelling of the P&I
data. Even though the analysis of P&I deaths generally gave
lower estimates of excess mortality, the estimate for the
pandemic season was somewhat higher than when analysing
all-cause mortality, with an excess mortality estimate of 96
deaths per year (20 per 100 000 in the population) for all age
groups. Due to what might be less noise in the P&I data, the
model uncertainty is smaller than in the analysis of overall
deaths, and we find a significant excess mortality during the
pandemic period.
Results from the EuroMOMO analysis are presented in
Table 4. Note again that the overall numbers do not equal
the sum of age-grouped numbers as they were estimated
using separate models. The estimates from EuroMOMO are
higher in the 15–64 and 65+ groups than the estimates using
Eq. (3). The total number of excess mortality in the
pandemic season was here estimated to be 252 deaths.
Discussion
We have compared the number of influenza-certified deaths
during the 2009 influenza pandemic in Norway with the
results from two models for estimating seasonal excess
mortality due to influenza. The model based on Eq. (1) gives
an estimated excess mortality of 56 deaths analysing all-
cause mortality and an estimate of 96 deaths using P&I-
certified deaths. Only the excess mortality found analysing
P&I deaths is significant. The EuroMOMO model gives an
estimate of 252 deaths, without stating uncertainty. The
numbers from the ad hoc registry for pandemic deaths at
NIPH are smaller than all of the above, with 32 deaths
attributed to influenza.
Age-grouped analysis suggests some excess mortality in the
lower age groups, although the estimates are far from signif-
icant, not noticeably different than in non-pandemic seasons.
Table 2. Estimated excess mortality using the estimator in Eq. (3), analysing both all-cause and P&I deaths, mean level of reported ILI and dominant
virus for all influenza seasons from 1998/1999 to 2010/2011
Season
Estimated excess mortality
using all-cause mortality
(95% CI)
Estimated excess mortality
using P&I deaths (95% CI)
Mean ILI per consultations
100 consultations Dominant virus
1998/1999 1363 (1193–1559) – 196 A/Sydney/5/97 (H3N2)
1999/2000 1520 (1326–1759) 394 (356–435) 142 A/Moscow/10/99 (H3N2)
2000/2001 339 (298–386) 80 (71–89) 067 A/New Caledonia/20/99 (H1N1)
2001/2002 761 (666–870) 203 (182–225) 098 A/Panama/2007/99 (H3N2)
2002/2003 629 (553–718) 132 (116–150) 089 No dominant virus
2003/2004 1083 (945–1242) 246 (219–275) 119 A/Fujian/411/2002 (H3N2)
2004/2005 784 (690–897) 151 (133–172) 103 A/California/6/2004 (H3N2)
2005/2006 631 (554–720) 125 (112–139) 092 B/Malaysia/2506/2004
2006/2007 818 (718–935) 190 (169–213) 103 A/Wisconsin/67/2005 (H3N2)
2007/2008 383 (337–437) 72 (64–80) 072 A/Solomon Island/3/2006 (H1N1)
and B/Florida/4/2006
2008/2009 542 (476–621) 114 (102–126) 105 A/Brisbane/10/2007 (H3N2)
2009/2010 56 (289–419) 96 (43–148) 216 A(H1N1)pdm09
2010/2011 607 (531–692) 118 (156–133) 097 B/Brisbane/60/08
ILI, influenza-like illness.
Gran et al.
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This findingmay seem to contradict the actual reported deaths
presented in Figure 2. An explanation can be that the enhanced
death surveillance during the pandemic, including a more
widespread use of laboratory tests for influenza, detectedmore
of the actual deaths than during non-pandemic periods,
especially among children and young adults.
Most of the estimated deaths occurred among the elderly.
However, the excess mortality estimates for the 65+ group
are lower during the 2009/2010 pandemic season than any
other seasons. The model in Eq. (1) gives an estimated excess
mortality of 30 deaths in the 65+ group in the pandemic
season, versus an average mortality of 766 deaths for all
seasons. The data on influenza-certified deaths also indicate a
non-typical age distribution, with a much higher proportion
of deaths taking place in the younger age groups. The major
part of the mortality was among people below the age of 65,
contrary to what we see during a typical seasonal winter
influenza outbreak.
Our estimated excess mortality using P&I-certified deaths
for all seasons was only about a fourth of the estimate using
all-cause deaths, but during the pandemic, the P&I estimate
was higher, and statistically significant, in contrast to the
estimates based on all-cause data. However, even though P&I
deaths have less noise than the all-cause mortality data, we
believe that using P&I deaths underestimates the mortality
burden of influenza, especially among the elderly. Several
recent articles point to influenza as a trigger of acute
myocardial infarction (AMI), which is a major cause of death
in most countries, including Norway. For instance, Warren-
Gash et al. found that 31–34% of AMI-associated deaths in
England and Wales were attributable to influenza.12 The
association was further supported by their self-controlled
cases series study.13 Foster et al. found similar results in
USA.14
The Poisson regression model in Eq. (1) gave similar
results as in Gran et al.2 for all overlapping seasons, even
Figure 3. Observed overall mortality, predicted mortality and reported number of influenza-like illness (ILI) cases per week (upper panel), together with
observed mortality and predicted mortality without ILI contribution with 95% confidence intervals (lower panel), for all age groups in Norway 1999–2011,
using the Poisson model in Eq. (1).
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though the data covered twice the time span as in the original
study. The results for the pandemic season were lower in
comparison with the results using the EuroMOMO model,
which partly can be explained by the use of the more
moderate estimator in Eq. (3) compared with the more
common estimator in Eq. (2). One should also note the large
uncertainty present when analysing the pandemic season
alone, especially when analysing all-cause mortality. It is
likely that uncertainty in the EuroMOMO estimates, which
are not reported, are of similar magnitude. Regarding other
model choices, such as the different ways to model week-to-
week and season-to-season variation, the results from the
EuroMOMO model and the different variants of the model
in Eq. (1) indicate that the excess mortality estimates are not
very sensitive to these model choices.
It is important to note that the data from the extended
pandemic death surveillance at NIPH and the Cause of Death
Registry are not directly comparable with the excess mortal-
ity estimated from the model in Eq. (1) and the EuroMOMO
method. As previously mentioned, it is often hard to discern
between influenza and other contributing factors. And
influenza is often seen as a contributing factor as it often
aggravates other underlying illnesses such as serious heart
and lung diseases. This is especially obvious in the elderly
population, above 65 years, as they more often have several
chronic underlying illnesses.
The mortality associated with the 2009 influenza pandemic
has been a topic in many recent papers,1 some of which use
excess mortality modelling. For example, Poisson models
were used to estimate the influenza-related excess mortality
in Hong Kong, before and during the pandemic season.15
Contrary to our analyses, they found that the mortality
during the whole of 2009 was comparable with those in the
preceding ten interpandemic years, with no real difference
among age groups. A study in USA,16 on the other hand,
estimated a higher excess mortality during the pandemic for
people below 65 years of age and lower excess mortality for
people in the 65+ group, compared with prior seasons. For
people below 15 years of age, the excess mortality was higher
than in any prior season between 1962/1963 and 2008/2009.
Another US study17 found a mean age of deaths of 37 years
during the pandemic, compared with an estimated mean age
of 76 during seasonal influenza epidemics. A study estimat-
ing the excess mortality in England and Wales between 1999
and 201018 found the highest mortality burden among the
75+ age group, with the lowest mortality during the 2009/
2010 pandemic season.
Excess mortality monitoring in England and Wales during
the pandemic19 showed excess all-cause mortality in the 5–
14 years age group, and in age groups >45 years ‘during a
period of very cold weather’. Surveillance data from
Finland20 and Denmark21 both showed high morbidity and
high rates of hospital admissions in younger age groups
compared with previous influenza seasons. A review of
pandemic deaths in Alberta, Canada,22 showed that the
mortality rate during the pandemic was the third highest in
the period 1983 to 2010 and that the mean age of deaths was
significantly younger by close to 30 years.
All the results suggest that the majority of the mortality
took place during the main wave of the pandemic (October–
Table 3. Regression results using the model in Eq. (1) and estimated excess mortality for age groups and overall analyses using the estimator in
Eq. (3)
Age
group b3 ILI (P-value)
b4 interaction (P-value)
for ILI 3 wave 1 and
wave 2
Mean estimated excess mortality per season
1998/1999–2010/2011 (rate per 100 000 pop.)
[95% CI]
Estimated excess mortality
pandemic season (rate per
100 000 pop.) [95% CI]
Analysing all-cause mortality
0–4 00376 (00575) 00203 (08600)
00535 (02251)
6 (21) [1 (03)–11 (37)] 7 (24) [15 (48)–30 (99)]
5–14 00879 (00232) 00097 (09345)
00905 (01959)
4 (07) [1 (02)–7 (11)] 3 (05) [5 (09)–13 (22)]
15–64 00055 (01787) 00106 (09791)
00061 (02143)
22 (07) [9 (03)–54 (18)] 13 (04) [96 (30)–128 (40)]
65+ 00339 (<00001) 00373 (<00001)
00345 (<00001)
727 (1043) [638 (915)–844 (1211)] 30 (41) [276 (379)–338 (464)]
All 00300 (<00001) 00314 (<00001)
00308 (<00001)
766 (166) [667 (144)–883 (191)] 56 (117) [228 (60)–380 (79)]
Analysing P&I-certified mortality
All 01322 (<00001) 00851 (00014)
01136 (<00001)
172 (37) [156 (34)–188 (40)] 96 (20) [43 (09)–148 (31)]
Gran et al.
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December), which is in line with the general perception of
the impact of the pandemic. It also appears that the mortality
in Norway peaked earlier, but was not higher than other
European countries. The fact that Norway had enhanced its
mortality surveillance and the extremely high media atten-
tion probably ensured very rapid reporting of the fatalities.
The results from the two models considered in this study
to different extent suggest an additional excess mortality
during the 2009 pandemic beyond what is reported to the
extended pandemic death surveillance at NIPH and the
Cause of Death registry. The analysis of P&I deaths in
particular finds an estimated excess mortality which is
significantly higher than what was reported. Results as a
whole indicates that this additional mortality is mainly found
among people in the oldest age groups, and one might also
expect that deaths among people in the older age groups in
general are less likely to be detected in pandemic surveillance
than deaths among younger age groups. However, it is
important to note that this higher estimated excess mortality
among the elderly is considerably lower during the 2009
Table 4. Observed number of overall deaths, expected deaths and
excess deaths, for age groups and overall, in Norway 2009–2010,
using the EuroMOMO consensus method
Weeks
Age
group
Observed
deaths
Expected
deaths
Excess deaths
(rate per
100 000 pop.)
29–52
(both
waves)
0–4 103 98 5 (17)
5–14 24 22 2 (03)
15–64 3049 2975 74 (23)
65+ 15 306 15 159 147 (201)
All 18 482 18 230 252 (52)
Figure 4. Observed P&I mortality, predicted mortality and reported number of influenza-like illness (ILI) cases per week (upper panel), together with
observed mortality and predicted mortality without ILI contribution with 95% confidence intervals (lower panel), for all age groups in Norway 2000–2011,
using the Poisson model in Eq. (1).
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pandemic than during regular influenza outbreaks. In other
words, the results from the modelling suggest that the 2009
pandemic was less severe for people in the older age groups
than during regular seasonal influenza. Reasons for this
could be that many elderly people had acquired immunity to
the pandemic virus through previous exposure to similar
influenza viruses23 or through vaccination against the A
(H1N1)pdm09 virus, which in Norway started at mid-
October 2009 and eventually covered around 45% of the
population, including the 65+ age group. The early and
atypical time of onset of the epidemic may also have played a
part.
From our results (Table 2), it is evident that there exists a
great variation in mortality between seasonal influenza
epidemics. This variation, perhaps partly mediated by
variation in age distribution, probably results from a
complex interplay between circulating influenza subtype
virulence and transmissibility and population immunity to
that virus. We note also that the pandemic seemed to be
causing a lower excess mortality than recent seasonal
epidemics. Thus, the dichotomy between seasonal influenza
and pandemic influenza may not be so important for public
health planning. Rather, it seems more important to assess
the severity of every influenza epidemic, as suggested by the
review of WHO’s response to the pandemic24 and followed
up by both WHO and Centers for Disease Control and
Prevention (CDC).25
Our findings may have several implications for public
health practice. Surveillance of deaths during a pandemic
may provide information for public health action. In
communications with the public, authorities need to be
absolutely clear about whether they are communicating
actual registered deaths or estimated excess deaths. Norway
should consider setting up a system, like the EuroMOMO
system, for continuous monitoring of excess deaths due to
influenza, other infectious diseases and extreme ambient
temperatures.
Further research is necessary to understand the true
mortality burden of influenza.1 This requires better criteria
for when and how to attribute deaths to influenza.
Data on reported deaths due to influenza have its
limitations, as influenza is often overseen as a contributing
underlying cause of death among people with other under-
lying diseases. However, registries of reported causes of
deaths serve an important purpose with a high information
yield on those actually detected, for example, on co-
morbidities, demography and virology. To give a good
assessment of the total number of deaths, excess mortality
modelling can be a better indicator.
Finally, it remains clear that deaths are only one part of the
burden of influenza. In Norway, the 2009 pandemic led to far
more cases of influenza, hospitalizations and intensive care
admissions than regular influenza epidemics.26–28 Estimates
of influenza-associated excess mortality during the A(H1N1)
pdm09 influenza pandemic suggest that the mortality might
have been higher than reported, especially among the 65+ age
group, but that these numbers were much lower than in
regular seasonal influenza epidemics.
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